Compare MYSZ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | OGEN |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.6M |
| IPO Year | N/A | N/A |
| Metric | MYSZ | OGEN |
|---|---|---|
| Price | $0.78 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 78.9K | ★ 98.1K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,512,000.00 | N/A |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.74 |
| 52 Week High | $4.48 | $18.90 |
| Indicator | MYSZ | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 48.15 |
| Support Level | $0.75 | $0.74 |
| Resistance Level | $0.84 | $0.88 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.08 | 77.71 |
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.